How were Medicines' earnings last quarter?

The Medicines Company (NASDAQ:MDCO) announced its quarterly earnings data on Wednesday, October, 30th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.80) by $0.12. During the same quarter in the prior year, the company posted ($0.70) earnings per share.

What other stocks do shareholders of Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medicines investors own include Micron Technology (MU) , NVIDIA (NVDA) , AbbVie (ABBV) , Gilead Sciences (GILD) , Alibaba Group (BABA) , Salesforce (CRM) , Bank of America (BAC) , Ionis Pharmaceuticals (IONS) , AT&T (T) and Alnylam Pharmaceuticals (ALNY) .

NASDAQ:MDCO

Medicines (MDCO) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Free MDCO Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $84.90
▼
$84.90
50-Day Range: $84.90
▼
$84.90
52-Week Range: $17.81
▼
$84.98

Volume: N/A
Average Volume: 9.55 million shs
Market Capitalization: $6.77 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Medicines alerts:

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Medicines Stock (NASDAQ:MDCO)

The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.

Ad Paradigm Press

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

MDCO Stock News Headlines

April 12, 2024 | marketbeat.com

No link between Ozempic, Wegovy and suicide, EU drug regulators say

Drug regulators in Europe have found no evidence that popular diabetes and weight-loss drugs like Ozempic and Wegovy are linked to a higher risk of suicidal thoughts or actions

April 4, 2024 | reuters.com

Mitsui and Rohto to buy $594 mln Chinese medicines company Eu Yan Sang

April 17, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 15, 2024 | investorplace.com

FIXX Stock Earnings: Homology Medicines Beats EPS for Q4 2023

February 23, 2024 | bbc.co.uk

Medicine in Britain, c.1250 to the present day

January 4, 2024 | marketwatch.com

Revolution Medicines started at outperform with $41 stock price target at Wedbush

December 30, 2023 | dailymail.co.uk

Warming on cancer risk in Chinese medicines

December 15, 2023 | bbc.com

Gene modified chickens 'lay medicines'

April 17, 2024 | Paradigm Press (Ad)

Could Bitcoin Literally FORCE This Crypto To Rocket Up?

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

November 27, 2023 | prnewswire.com

AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

October 23, 2023 | ft.com

EU plans for countries to share medicines in case of shortage

October 20, 2023 | rttnews.com

CVS To Remove Some Cold, Cough Medicines With Phenylephrine

October 4, 2023 | bizjournals.com

How Revolution Medicines chased down EQRx's $1 billion cash prize

October 4, 2023 | benzinga.com

Cancer Drug Maker 3D Medicines Inc. Trading Higher After Company Announces It Will Repurchase Up To 10% Of Outstanding Shares

August 21, 2023 | prnewswire.com

Approval of an Orphan Disease Application for its lead product, the Cellspan Esophageal Implant by the European Medicines Agency

August 17, 2023 | prnewswire.com

European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy

July 26, 2023 | markets.businessinsider.com

Everest Medicines Announces Commercial Launch and First Prescription for XERAVA® in China

July 11, 2023 | cnbc.com

EU expands Wegovy, Ozempic probe over suicide risks to include other weight loss, diabetes drugs

June 26, 2023 | investing.com

Point72/Steven Cohen Increases Stake in Praxis Precision Medicines to 8.9%

June 20, 2023 | marketwatch.com

Does Pet Insurance Cover Medication?

March 26, 2023 | prnewswire.com

Everest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash Reserves

March 19, 2023 | ft.com

Medicines regulator seeks to shake off UK ‘isolationist’ label with new alliance

March 15, 2023 | prnewswire.com

Bioprojet: WAKIX® (pitolisant) receives approval for the treatment of narcolepsy in children over 6 years of age, a rare, under-diagnosed condition

March 12, 2023 | prnewswire.com

Everest Medicines Announces Silicon Valley Bank Developments Have Minimal Impact on Company

March 7, 2023 | benzinga.com

Pharma Mafia Wants To Conquer Cannabis: Can You Patent A Plant? Jazz Is Trying

February 28, 2023 | benzinga.com

Revolution Medicines' Early-Data Validation For Cancer Program Wins Price Target Boost By This Analyst

February 28, 2023 | benzinga.com

Why Revolution Medicines Shares Are Trading Higher Today

See More Headlines

Receive MDCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/30/2019
Today: 4/17/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:MDCO
CUSIP: 58468810
CIK: 1113481
Web: www.themedicinescompany.com
Phone: 973-290-6000
Fax: N/A
Employees: 62
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.91)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-123,160,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -25.70%

Debt

Debt-to-Equity Ratio: 21.45
Current Ratio: 0.77
Quick Ratio: 0.77

Sales & Book Value

Annual Sales: $6.14 million
Price / Sales: 1,102.36
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.30) per share
Price / Book: -283.00

Miscellaneous

Outstanding Shares: 79,723,000
Free Float: N/A
Market Cap: $6.77 billion
Optionable: Optionable
Beta: 1.10

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Mark Timney (Age 54)
CEO & Director
Mr. Christopher J. Visioli (Age 43)
CFO & Treasurer
Mr. Stephen M. Rodin J.D. (Age 43)
Exec. VP, Gen. Counsel & Sec.
Dr. Clive A. Meanwell (Age 61)
Chief Innovation Officer & Director
Dr. Goutham Krishna Gorti
VP & Head of Investor Relations

Key Competitors

View All Competitors

MDCO Stock Analysis - Frequently Asked Questions

How were Medicines' earnings last quarter?: The Medicines Company (NASDAQ:MDCO) announced its quarterly earnings data on Wednesday, October, 30th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.80) by $0.12. During the same quarter in the prior year, the company posted ($0.70) earnings per share.
What other stocks do shareholders of Medicines own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Medicines investors own include Micron Technology (MU), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Salesforce (CRM), Bank of America (BAC), Ionis Pharmaceuticals (IONS), AT&T (T) and Alnylam Pharmaceuticals (ALNY).

This page (NASDAQ:MDCO) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Medicines (MDCO) Stock Price, News & Analysis

About Medicines Stock (NASDAQ:MDCO)

MDCO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

MDCO Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info